NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:NSCI - CA63000Y1034 - Common Stock
0.17 CAD
+0.01 (+3.03%)
We assign a fundamental rating of 3 out of 10 to NSCI. NSCI was compared to 18 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NSCI have multiple concerns. NSCI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- NSCI had negative earnings in the past year.
- NSCI had a positive operating cash flow in the past year.
- In the past 5 years NSCI always reported negative net income.
- NSCI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -33.37%, NSCI belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
- The Return On Equity of NSCI (-109.99%) is better than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.37% | ||
| ROE | -109.99% | ||
| ROIC | N/A |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NSCI has a Gross Margin of 26.96%. This is in the lower half of the industry: NSCI underperforms 66.67% of its industry peers.
- NSCI's Gross Margin has declined in the last couple of years.
- NSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
2. Health
2.1 Basic Checks
- NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- NSCI has more shares outstanding than it did 1 year ago.
- NSCI has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, NSCI has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -0.85, we must say that NSCI is in the distress zone and has some risk of bankruptcy.
- NSCI has a Altman-Z score of -0.85. This is in the better half of the industry: NSCI outperforms 77.78% of its industry peers.
- NSCI has a debt to FCF ratio of 132.94. This is a negative value and a sign of low solvency as NSCI would need 132.94 years to pay back of all of its debts.
- NSCI has a better Debt to FCF ratio (132.94) than 100.00% of its industry peers.
- A Debt/Equity ratio of 1.00 indicates that NSCI is somewhat dependend on debt financing.
- NSCI has a Debt to Equity ratio of 1.00. This is in the better half of the industry: NSCI outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1 | ||
| Debt/FCF | 132.94 | ||
| Altman-Z | -0.85 |
ROIC/WACCN/A
WACC8.43%
2.3 Liquidity
- NSCI has a Current Ratio of 0.86. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
- NSCI's Current ratio of 0.86 is fine compared to the rest of the industry. NSCI outperforms 77.78% of its industry peers.
- A Quick Ratio of 0.62 indicates that NSCI may have some problems paying its short term obligations.
- NSCI has a Quick ratio of 0.62. This is in the better half of the industry: NSCI outperforms 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.62 |
3. Growth
3.1 Past
- The earnings per share for NSCI have decreased strongly by -36.84% in the last year.
- Looking at the last year, NSCI shows a decrease in Revenue. The Revenue has decreased by -2.93% in the last year.
- The Revenue has been growing by 40.32% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-12.16%
3.2 Future
- Based on estimates for the next years, NSCI will show a very strong growth in Earnings Per Share. The EPS will grow by 36.21% on average per year.
- Based on estimates for the next years, NSCI will show a small growth in Revenue. The Revenue will grow by 5.74% on average per year.
EPS Next Y50%
EPS Next 2Y40.78%
EPS Next 3Y38.46%
EPS Next 5Y36.21%
Revenue Next Year-3.67%
Revenue Next 2Y-1.62%
Revenue Next 3Y1.13%
Revenue Next 5Y5.74%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- NSCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NSCI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 94.44% of the companies in the same industry are more expensive than NSCI, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, NSCI is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 139.59 | ||
| EV/EBITDA | 127.08 |
4.3 Compensation for Growth
- NSCI's earnings are expected to grow with 38.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.78%
EPS Next 3Y38.46%
5. Dividend
5.1 Amount
- No dividends for NSCI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX-V:NSCI (1/16/2026, 7:00:00 PM)
0.17
+0.01 (+3.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-24 2025-11-24/amc
Earnings (Next)04-22 2026-04-22/amc
Inst Owners8.47%
Inst Owner ChangeN/A
Ins Owners3.93%
Ins Owner ChangeN/A
Market Cap19.68M
Revenue(TTM)41.74M
Net Income(TTM)-12.38M
Analysts80
Price Target0.64 (276.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.02%
Min Revenue beat(2)-14.08%
Max Revenue beat(2)-7.95%
Revenue beat(4)1
Avg Revenue beat(4)-5.27%
Min Revenue beat(4)-14.08%
Max Revenue beat(4)8.09%
Revenue beat(8)5
Avg Revenue beat(8)12.52%
Revenue beat(12)6
Avg Revenue beat(12)3.83%
Revenue beat(16)8
Avg Revenue beat(16)1.55%
PT rev (1m)0%
PT rev (3m)-24.24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-175%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.47 | ||
| P/FCF | 139.59 | ||
| P/OCF | 10.53 | ||
| P/B | 1.75 | ||
| P/tB | N/A | ||
| EV/EBITDA | 127.08 |
EPS(TTM)-0.05
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0
FCFY0.72%
OCF(TTM)0.02
OCFY9.5%
SpS0.36
BVpS0.1
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.37% | ||
| ROE | -109.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.96% | ||
| FCFM | 0.34% |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score5
Asset Turnover1.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1 | ||
| Debt/FCF | 132.94 | ||
| Debt/EBITDA | 41.54 | ||
| Cap/Depr | 43.06% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 692.22% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | -0.85 |
F-Score5
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y50%
EPS Next 2Y40.78%
EPS Next 3Y38.46%
EPS Next 5Y36.21%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-12.16%
Revenue Next Year-3.67%
Revenue Next 2Y-1.62%
Revenue Next 3Y1.13%
Revenue Next 5Y5.74%
EBIT growth 1Y35.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.21%
EBIT Next 3Y70.03%
EBIT Next 5Y55.27%
FCF growth 1Y100.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y113.27%
OCF growth 3YN/A
OCF growth 5Y33.1%
NANALYSIS SCIENTIFIC CORP / NSCI.CA FAQ
What is the ChartMill fundamental rating of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to NSCI.CA.
Can you provide the valuation status for NANALYSIS SCIENTIFIC CORP?
ChartMill assigns a valuation rating of 3 / 10 to NANALYSIS SCIENTIFIC CORP (NSCI.CA). This can be considered as Overvalued.
What is the profitability of NSCI stock?
NANALYSIS SCIENTIFIC CORP (NSCI.CA) has a profitability rating of 2 / 10.
What is the financial health of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?
The financial health rating of NANALYSIS SCIENTIFIC CORP (NSCI.CA) is 3 / 10.
What is the earnings growth outlook for NANALYSIS SCIENTIFIC CORP?
The Earnings per Share (EPS) of NANALYSIS SCIENTIFIC CORP (NSCI.CA) is expected to grow by 50% in the next year.